Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,397,209 | $562,656,064 | -15% | 0.83% |
| 2. | 347,100 | $139,777,170 | +66% | 0.02% | |
| 3. | Millennium Management Israel Englander | 310,643 | $125,095,936 | +96% | 0.06% |
| 4. | D E Shaw D. E. Shaw | 265,684 | $106,990,947 | +92% | 0.07% |
| 5. | AQR Capital Management Cliff Asness | 245,785 | $98,977,658 | -49% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $196.34 | 4,243 | Officer, Director | 73,754 | 2021-08-19 | Filing | |
| $195.14 | 5,757 | Officer, Director | 69,511 | 2021-08-19 | Filing | |
| $197.91 | 15,000 | Director | 41,210 | 2021-08-02 | Filing | |
| $218.79 | 3,905 | Director | 26,210 | 2020-11-10 | Filing | |
| $217.49 | 4,270 | Director | 22,305 | 2020-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $475.34 | 530 | Officer | 58,539 | 2025-02-27 | Filing | |
| $475.34 | 2,650 | Officer | 19,352 | 2025-02-27 | Filing | |
| $480.00 | 1,272 | Officer | 32,974 | 2025-02-27 | Filing | |
| $480.95 | 354 | Officer | 64,031 | 2025-02-25 | Filing | |
| $480.95 | 1,767 | Officer | 24,484 | 2025-02-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,325,695 | $11,406,666,988 | 1.73% | |
| 2. | 23,258,288 | $9,366,112,578 | 0.16% | |
| 3. | 21,825,470 | $8,789,116,493 | 0.17% | |
| 4. | 11,979,405 | $4,823,868,882 | 0.19% | |
| 5. | 10,428,951 | $4,199,713,394 | 0.86% |
News See All
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Call Transcript February 10, 2025Vertex Pharmaceuticals Incorporated misses on earnings expectations.
Jim Cramer Shed Light on These 9 Stocks
Jim Cramer, the host of Mad Money, has been considering the uncertainty surrounding 2025 and the ongoing macroeconomic challenges that are sparking important questions.
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Jim Cramer's Bold Predictions About These 10 Healthcare Stocks
Healthcare has been one of Jim Cramer's favorite topics lately.
Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options
In his second appearance on Squawk on the Street after the Fed's interest rate cut, Jim Cramer had a lot to say about the Fed's decision and the Personal Consumption Expenditure (PCE) data release.
10 Stocks That Will Make You Rich In 2025
Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock market in 2025.
Jim Cramer Talked About These 17 Stocks After The Fed's Rate Cut
The Federal Reserve created quite a bit of turmoil in the stock market on Wednesday when despite cutting interest rates, it signaled to investors that the journey to low rates was far from over and would...
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third quarter 2024, investor letter. A copy of the letter can be downloaded here.
6 Stocks Jim Cramer Talked About This Week
Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious opportunities, particularly with cult stocks, which in hindsight appear to be clear success stories.
Billionaire Hedge Funds
